Cargando…

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma

Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) in tumor microenvironmental cells is associated with MM growth suppression. The absence of NEK2 leads to both fewer tumor-as...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yan, Sun, Fumou, Alapat, Daisy V., Wanchai, Visanu, Mery, David, Guo, Wancheng, Cao, Huojun, Zhu, Yuqi, Ashby, Cody, Bauer, Michael Anton, Nookaew, Intawat, Siegel, Eric R., Ying, Jun, Chen, Jin-Ran, Gai, Dongzheng, Peng, Bailu, Xu, Hongwei, Bailey, Clyde, Al Hadidi, Samer, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Chesi, Marta, Bergsagel, P. Leif, van Rhee, Frits, Janz, Siegfried, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591052/
https://www.ncbi.nlm.nih.gov/pubmed/37794587
http://dx.doi.org/10.1016/j.xcrm.2023.101214
Descripción
Sumario:Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) in tumor microenvironmental cells is associated with MM growth suppression. The absence of NEK2 leads to both fewer tumor-associated macrophages (TAMs) and inhibitory T cells. NEK2 expression in myeloid progenitor cells promotes the generation of functional TAMs when stimulated with MM conditional medium. Clinically, high NEK2 expression in MM cells is associated with increased CD8(+) T effector memory cells, while low NEK2 is associated with an IFN-γ gene signature and activated T cell response. Inhibition of NEK2 upregulates PD-L1 expression in MM cells and myeloid cells. In a mouse model, the combination of NEK2 inhibitor INH154 with PD-L1 blockade effectively eliminates MM cells and prolongs survival. Our results provide strong evidence that NEK2 inhibition may overcome tumor immune escape and support its further clinical development.